Title:Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?
Volume: 10
Issue: 2
Author(s): Paraskevaidis Ioannis, Palios John, Parissis John, Filippatos Gerasimos and Anastasiou-Nana Maria
Affiliation:
Keywords:
Cardiovascular disease, chronic heart failure, citalopram, coronary artery disease, dapoxetine, depression,
escitalopram, fluoxetine, fluvoxamin, paroxetine, selective serotonin re-uptake inhibitors, sertraline, vilazodone
Abstract: Depression is a common co-morbidity in patients with cardiovascular diseases such as chronic coronary artery
disease, acute coronary syndromes, post by-pass surgery and chronic heart failure. The presence of depression is
independently associated with a decline in health status and an increase in the risk of hospitalization and death for patients
with coronary artery disease or congestive heart failure. Novel treatment modalities such as selective serotonin re-uptake
inhibitors (SSRIs) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure
patients interacting with the common pathophysiological mechanisms of depression and cardiovascular disease. This
review summarizes current experimental and clinical evidence regarding the effects of SSRIs on platelet functions,
immune and neurohormonal activation, and cardiac rhythm disturbances in patients with cardiovascular disease.
